Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by Hiddensecretson Jul 28, 2021 8:29pm
153 Views
Post# 33618778

RE:RE:From the $ 12 million: payments made up to date for BLOWFISH

RE:RE:From the $ 12 million: payments made up to date for BLOWFISHThey are in stage 2 of clincial trials, clincal 1 was a success.

On June 3rd, 2021, David spoke intensively of Blowfish technology on page 17 and 18 and, he states that balance of $ 1 million is due when they hit several milestones, one of them is getting EUA approval. 

That has not happened yet.   The current percentage is 14% for MEDV to go up to 40% upon approval.

Those few posters who allude to a cancelled deal are nothing but FEAR MONGERERS.

The company made no such statement and they will not engage with deceptive posts. 

Stan Bharti invested $ 12 million, that should tell you alot about the seriousness of his investment to get blowfish technology approved. 

mpo
<< Previous
Bullboard Posts
Next >>